Postoperative oral milvexian twice daily resulted in a 12% incidence of venous thromboembolism, significantly lower than the prespecified 30% benchmark (one-sided P<0.001).
RCT (n=1,242)
parallel-group
Does postoperative milvexian prevent venous thromboembolism in patients undergoing knee arthroplasty?
Postoperative factor XIa inhibition with oral milvexian effectively prevents venous thromboembolism after knee arthroplasty with a bleeding risk comparable to enoxaparin.
Absolute Event Rate: 12% vs 21%
p-value: p=<0.001
BACKGROUND: Factor XIa inhibitors for the prevention and treatment of venous and arterial thromboembolism may be more effective and result in less bleeding than conventional anticoagulants. Additional data are needed regarding the efficacy and safety of milvexian, an oral factor XIa inhibitor. METHODS: In this parallel-group, phase 2 trial, we randomly assigned 1242 patients undergoing knee arthroplasty to receive one of seven postoperative regimens of milvexian (25 mg, 50 mg, 100 mg, or 200 mg twice daily or 25 mg, 50 mg, or 200 mg once daily) or enoxaparin (40 mg once daily). The primary efficacy outcome was venous thromboembolism (which was a composite of asymptomatic deep-vein thrombosis, confirmed symptomatic venous thromboembolism, or death from any cause). The principal safety outcome was bleeding. RESULTS: Among the patients receiving milvexian twice daily, venous thromboembolism developed in 27 of 129 (21%) taking 25 mg, in 14 of 124 (11%) taking 50 mg, in 12 of 134 (9%) taking 100 mg, and in 10 of 131 (8%) taking 200 mg. Among those receiving milvexian once daily, venous thromboembolism developed in 7 of 28 (25%) taking 25 mg, in 30 of 127 (24%) taking 50 mg, and in 8 of 123 (7%) taking 200 mg, as compared with 54 of 252 patients (21%) taking enoxaparin. The dose-response relationship with twice-daily milvexian was significant (one-sided P<0.001), and the 12% incidence of venous thromboembolism with twice-daily milvexian was significantly lower than the prespecified benchmark of 30% (one-sided P<0.001). Bleeding of any severity occurred in 38 of 923 patients (4%) taking milvexian and in 12 of 296 patients (4%) taking enoxaparin; major or clinically relevant nonmajor bleeding occurred in 1% and 2%, respectively; and serious adverse events were reported in 2% and 4%, respectively. CONCLUSIONS: Postoperative factor XIa inhibition with oral milvexian in patients undergoing knee arthroplasty was effective for the prevention of venous thromboembolism and was associated with a low risk of bleeding. (Funded by Bristol Myers Squibb and Janssen Research and Development; AXIOMATIC-TKR ClinicalTrials.gov number, NCT03891524.).
Weitz et al. (Mon,) conducted a rct in knee arthroplasty (n=1,242). Milvexian vs. Enoxaparin (40 mg once daily) was evaluated on venous thromboembolism (composite of asymptomatic deep-vein thrombosis, confirmed symptomatic venous thromboembolism, or death from any cause) (p=<0.001). Postoperative oral milvexian twice daily resulted in a 12% incidence of venous thromboembolism, significantly lower than the prespecified 30% benchmark (one-sided P<0.001).